Home
Clinical Trials
Clinical Study of TQA3605 Tab...

Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Last Updated: 2025-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-14

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a phase II multicenter, randomized, double-blind, placebo controlled study designed to evaluate the efficacy and safety in LLV subjects and demonstrate that TQA3605 tablets combined with oral NAs drugs can improve the efficacy and safety of LLV subjects compared with oral NAs drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

NCT06150014

Chronic Hepatitis b

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

NCT06990776

Chronic Hepatitis B

WITHDRAWN PHASE2

Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

NCT06706310

Chronic Hepatitis B

ACTIVE_NOT_RECRUITING PHASE2

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B

NCT06566248

Chronic Hepatitis B

RECRUITING PHASE2

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

NCT04180150

Chronic Hepatitis B

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HBV Infection With LLV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TQA3605 Placebo plus NAs

TQA3605 placebo plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks

Group Type PLACEBO_COMPARATOR

TQA3605 Placebo plus NAs

Intervention Type DRUG

Placebo without drug substance

100mg TQA3605 tablets plus NAs

100mg TQA3605 tablets plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks

Group Type EXPERIMENTAL

TQA3605 tablets plus NAs

Intervention Type DRUG

TQA3605 tablets is core protein regulator

200mg TQA3605 tablets plus NAs

200mg TQA3605 tablets plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks

Group Type EXPERIMENTAL

TQA3605 tablets plus NAs

Intervention Type DRUG

TQA3605 tablets is core protein regulator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TQA3605 tablets plus NAs

TQA3605 tablets is core protein regulator

Intervention Type DRUG

TQA3605 Placebo plus NAs

Placebo without drug substance

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18-65 (including boundary values), male or female.
* At the time of screening, etiological or clinical or pathological evidence of hepatitis B virus infection has been more than 1 year; HBsAg positive, 10 IU/mL \<HBV DNA≤2000 IU/mL, ALT≤3×ULN (upper limit of normal); No obvious cirrhosis was found by the researchers.
* Continuous administration of any nucleoside (acid) analogues for more than 1 year and a stable regimen of ≥6 months prior to screening.
* Able to communicate well with researchers, understand and comply with the requirements of the study, understand and sign the informed consent.
* Male subjects with fertile female partners or female subjects of childbearing age were willing to voluntarily take effective contraceptive measures within 3 months after screening.

Exclusion Criteria

* Pregnant (positive pregnancy test) or breastfeeding women.
* Co-infection with other viruses such as hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, human immunodeficiency virus, syphilis.
* A history of cirrhosis or evidence of significant fibrosis or cirrhosis at pre-screening/screening time.
* The subject had a history of hepatocellular carcinoma (HCC) before or at the time of screening, or was suspected of HCC.
* A history of malignant tumors within 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection.
* Subjects with other chronic liver diseases, including but not limited to autoimmune liver disease, alcoholic liver disease, and hepatolenticular degeneration.
* Have previously received organ transplantation and bone marrow transplantation.
* Abnormal laboratory examination indicators that do not meet the requirements of the program during screening.
* Poorly controlled thyroid disease, or clinically significant thyroid dysfunction.
* Autoimmune diseases include but are not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, psoriasis, autoimmune uveitis, etc.;
* In addition to liver disease, there are significant systemic or major diseases, including recent congestive heart failure, unstable coronary heart disease, arterial revasodilation, respiratory disease, digestive disease, renal insufficiency, stroke, transient ischemic attack, organ transplantation, psychiatric disease, etc. Uncontrolled systemic disease: poor blood pressure control; Diabetes has poor blood sugar control.
* Received any systemic antitumor (including radiation) or immunosuppressive therapy (including biological immune inhibitors), or immunomodulatory therapy (including non-biological immunomodulatory oral drugs) in the 6 months prior to screening.
* Receiving high doses of systemic corticosteroids within 3 months prior to the screening period.
* A history of alcohol and drug abuse within 1 year prior to the screening period.
* Blood transfusion ≤2 months before screening and/or blood donation ≤1 month before screening. Note: Participants were not allowed to donate blood throughout the study period.
* Have a history of allergy to the experimental drug or its excipients.
* Participated in clinical trials of hepatitis B core protein allosteric regulators.
* The subject has participated in a clinical trial and received the investigational drug during the period prior to the first administration of the study: 5 half-lives or twice the duration of the biological effect of the study treatment or 90 days (if the half-life or duration is unknown).
* History or status of cardiovascular disease: history of risk factors for tip torsion ventricular tachycardia, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory tests. Family history of long QT syndrome or Brugada syndrome. The Electrocardiogram (ECG) showed clinically significant abnormalities. Heart Rate (HR)≤45 bpm.
* Those that researchers believe should not be included.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.